QSP Summit 2025: A New Standard in the Future of Drug Development

QSP uses computational modeling and experimental data to bridge the gap between biology and pharmacology. By using a quantitative mathematical model, it examines interactions between drugs, biological systems, and diseases, effectively delivering a robust platform for predicting clinical outcomes. The summit spotlighted the extraordinary advancements and adoption of QSP solutions. QSP is no longer an emerging methodology; it is becoming the new standard in drug development. Thanks to increasing regulatory acceptance, cutting-edge AI advancements, and its application in solving complex biological puzzles, QSP is proving to be a game-changer. Users of QSP modeling showcased how QSP is reframing drug development while fostering collaboration and dialogue on its next steps.

QSP challenges researchers and drug developers to understand biology on a deeper level. It doesn’t simply accept assumptions; it identifies gaps and forces necessary questions to be asked. This rigor results in robust, validated models, prerequisites for effective and innovative pharmacology.

One standout application is hypothesis generation. QSP enables scientists to simulate clinical trial scenarios that are otherwise prohibitively expensive or impractical to test experimentally. This simulation capability not only builds confidence in efficacy projection but also ensures cost efficiency.

Another advantage is scalability. Each QSP model is a repository of knowledge, growing more valuable with every application. Learnings from one therapeutic area or modality can often be applied to others, multiplying cost savings and fostering innovation.

A QSP model’s potential extends far beyond its initial application. Models developed for one reference indication can continue delivering value to subsequent indications, streamlining clinical dosage optimization and strategic decisions. Thanks to this long-term utility, regulators are increasingly endorsing QSP approaches as standard.

Further, QSP addresses the limitations of traditional animal models. By aligning with the FDA’s push to reduce, refine, and replace animal testing, QSP- a part of Certara’s Non-Animal Navigator solution– offers predictive, mechanistic alternatives that optimize preclinical safety evaluations.

Perhaps most exciting is QSP’s role in enabling virtual patient populations and digital twins. These cutting-edge applications are particularly impactful for rare diseases and pediatric populations, where clinical trials are often unfeasible. Through QSP modeling, drug developers can explore personalized therapies and refine treatments with unprecedented precision, bypassing dose levels that would traditionally require live trials.

The success of the QSP Summit 2025 underscores the undeniable value of QSP in the pharmaceutical industry. This isn’t just a tool; it’s a paradigm shift. The collaborative energy and shared insights from the summit are paving the way for continued innovation, ensuring that QSP remains at the forefront of pharmacological science.

Certara is committed to leading this charge, providing the tools, expertise, and community required to drive these advancements forward. The momentum is clear—QSP is shaping the future of drug development in real-time.

QSP isn’t just the future of pharmacology. It’s happening now, and we invite you to be part of it. Join us at Certainty EU (October 1-2 | Barcelona, Spain) for the next chapter.

For more information about Certara’s QSP solutions and upcoming events, visit Certara’s QSP Services. Together, we’re transforming drug development.